Get the Stockscreener App
43.56
0.11%
0.065
Gsk Plc Adr stock is traded at $43.56, with a volume of 1.46M.
It is up +0.11% in the last 24 hours and up +8.74% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$43.50
Open:
$43.76
24h Volume:
1.46M
Relative Volume:
0.30
Market Cap:
$88.63B
Revenue:
$40.95B
Net Income/Loss:
$5.16B
P/E Ratio:
20.30
EPS:
2.1459
Net Cash Flow:
$5.47B
1W Performance:
-4.31%
1M Performance:
+8.74%
6M Performance:
+27.60%
1Y Performance:
+14.54%
1-Day Range:
$43.50
$43.90
1-Week Range:
$43.04
$44.96
52-Week Range:
$31.71
$45.59
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
43.56 | 87.51B | 40.95B | 5.16B | 5.47B | 2.1459 |
|
LLY
Lilly Eli Co
|
849.79 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.11 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.32 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.69 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.66 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - The Globe and Mail
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why GSK (GSK) is a Top Value Stock for the Long-Term - sharewise.com
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Bought by Farther Finance Advisors LLC - Defense World
GlaxoSmithKline (GSK) Gets a Hold from Barclays - The Globe and Mail
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
Top Technology Executives Recognized at the 2025 BayAreaCIO ORBIE Awards - GlobeNewswire Inc.
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why GSK (GSK) is a Strong Growth Stock - sharewise.com
Rhumbline Advisers Increases Holdings in GSK PLC Sponsored ADR $GSK - Defense World
Parallel Advisors LLC Acquires 1,718 Shares of GSK PLC Sponsored ADR $GSK - Defense World
First Bank & Trust Takes Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Rep. Lisa C. McClain Purchases Shares of GSK PLC Sponsored ADR (NYSE:GSK) - MarketBeat
Bard Financial Services Inc. Raises Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Douglas Lane & Associates LLC Decreases Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):